2006
DOI: 10.1016/s1888-4415(06)76402-5
|View full text |Cite
|
Sign up to set email alerts
|

Utilización de aprotinina como agente hemostático en la prótesis total de cadera

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2015
2015
2015
2015

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(1 citation statement)
references
References 25 publications
0
1
0
Order By: Relevance
“…Simulations were performed for the three days post-surgery, using the clearance of synovial liquid values previously reported (20.42 ± 11.3 mL/h for the first day; 9.33 ± 11.02 mL/h for the second day and 4.11 ± 2.95 mL/h for the third day) [28] and considering that the distribution of the antibiotic from the location of the implant to the systemic circulation is negligible. Bioactivity was evaluated using MIC distributions for Pseudomonas aeruginosa (MIC = 0.25-1 μg/mL), S. aureus (MIC = 0.12-0.5 μg/mL) and Escherichia coli (MIC = 0.016-0.004 μg/mL) [29] and calculating the percentage of patients whose levels of antibiotic at the site of the implant would be higher than the MIC.…”
Section: Methodsmentioning
confidence: 99%
“…Simulations were performed for the three days post-surgery, using the clearance of synovial liquid values previously reported (20.42 ± 11.3 mL/h for the first day; 9.33 ± 11.02 mL/h for the second day and 4.11 ± 2.95 mL/h for the third day) [28] and considering that the distribution of the antibiotic from the location of the implant to the systemic circulation is negligible. Bioactivity was evaluated using MIC distributions for Pseudomonas aeruginosa (MIC = 0.25-1 μg/mL), S. aureus (MIC = 0.12-0.5 μg/mL) and Escherichia coli (MIC = 0.016-0.004 μg/mL) [29] and calculating the percentage of patients whose levels of antibiotic at the site of the implant would be higher than the MIC.…”
Section: Methodsmentioning
confidence: 99%